Business Wire

MIRJAM-HELIN-COMPETITION

8.2.2024 12:01:37 CET | Business Wire | Press release

Share
Singers From 25 Countries to the International Mirjam Helin Competition

56 talented young singers were selected to compete for the first prize of 50,000 euro in the Mirjam Helin competition in Helsinki, Finland next June.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208343535/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

One of the 2019 winners Johanna Wallroth singing with the Finnish Radio Symphony Orchestra and conductor Hannu Lintu. Photo by Heikki Tuuli.

Based on video pre-screening, the Mirjam Helin competition selected 56 out of 485 applicants for the competition in Helsinki next June. Altogether 61 nationalities were represented among the applicants.

Soile Isokoski, opera singer and chair of the Mirjam Helin competition jury is delighted to see that the competition attracted such highly promising and talented singers.

“Naturally, the first criterion is the applicant’s voice, but this is just the starting point. We look for singers who perform the music as it is intended but who also go beyond the notes, bring the song to life and master all the different genres. Verdi and Mozart cannot be sung in the same way,” Isokoski says.

South Korea has the highest number of applicants accepted to the competition, thirteen in total. Four of the competitors are from Finland. The competitors represent 25 nationalities, with participants from countries such as Armenia, Germany, Costa Rica, China, the United States, Croatia and Australia. For a full list of competitors, see mirjamhelin.fi.

The preliminary competition with piano accompaniment will take place from 3 to 6 June 2024. The jury selects 16–20 singers for the semifinals, and six will be eligible for the orchestral finals on 12 June. In the orchestral finals, the singers will perform with the Helsinki Philharmonic, led by Sir Mark Elder.

The jury members are soprano Dawn Upshaw, mezzosoprano Randi Stene, baritone Bo Skovhus, pianist Keval Shah and chair, soprano Soile Isokoski.

The Mirjam Helin competition is celebrating its 40th anniversary this year. The winner will be awarded the first prize of 50,000 euro; the second prize is 40,000 euro, the third prize 30,000 euro, and the other three finalists will receive 10,000 euro each. The finalists will also have opportunities to perform at Finnish music festivals and with Finnish orchestras.

The Finnish Cultural Foundation has been organizing the international Mirjam Helin competition since 1984. The competition is founded on Mirjam ja Hans Helin’s large donation. Professor Mirjam Helin’s (1911–2006) aim was to establish an international singing competition in Finland and to make it the most prestigious competition globally.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240208343535/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye